🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for HR-positive, HER2-negative Advanced Breast Cancer

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. NCT07062965Phase 3433 sites📍 Anchorage📍 Chandler📍 Gilbert Pfizer · Tests: PF-07248144, Fulvestrant, Everolimus, Exemestane Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors NCT07288359Phase 1, Phase 216 sites📍 Atlanta📍 Nashville📍 San Antonio Novartis Pharmaceuticals · Tests: GVV858, Fulvestrant, Letrozole FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer NCT05304962Phase 18 sites📍 La Jolla📍 Los Angeles📍 Port Saint Lucie Regor Pharmaceuticals Inc. · Tests: RGT-419B, RGT-419B in combination with hormonal therapy Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer NCT06982521Phase 3243 sites📍 Gilbert📍 Beverly Hills📍 Duarte Relay Therapeutics, Inc. · Tests: Zovegalisib, Capivasertib, Fulvestrant Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) NCT06757634Phase 3239 sites📍 Jonesboro📍 Little Rock📍 Duarte Celcuity Inc · Tests: Arm A: Gedatolisib + Palbociclib + Fulvestrant, Arm B: Ribociclib + Fulvestrant, Arm C: Gedatolisib + Palbociclib + Let… Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer NCT06837792Phase 21 site📍 Seoul Yonsei University · Tests: Experimental treatment arm, Control treatment arm SNF Platform Study of HR+/ HER2-advanced Breast Cancer NCT05594095Phase 21 site📍 Shanghai Fudan University · Tests: PIK3CA inhibitor, AKT inhibitor, Carrelizumab, Famitinib, Fluzoparib Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer NCT05744687Phase 2, Phase 39 sites📍 Fuzhou📍 Guangzhou📍 Guiyang Shanghai Pharmaceuticals Holding Co., Ltd · Tests: SPH4336 Tablets 400mg, SPH4336 Tablets Placebo A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer NCT05851014Phase 352 sites📍 Bengbu📍 Hefei📍 Hefei Genor Biopharma Co., Ltd. · Tests: GB491 combined with Letrozole, Placebo combined with Letrozole Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer NCT07558733Phase 1, Phase 27 sites📍 Los Angeles📍 Lone Tree📍 Springfield Faeth Therapeutics · Tests: Serabelisib, Sapanisertib, Fulvestrant Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer NCT07180160Phase 21 site📍 Shanghai Wenjin Yin · Tests: QL1706, CDK4/6 inhibitor, Fulvestrant Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) NCT05579366Phase 1, Phase 266 sites📍 Phoenix📍 Tucson📍 Los Angeles Genmab · Tests: Rina-S, Carboplatin, Bevacizumab, Pembrolizumab, Erythromycin Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer. NCT07227233Phase 21 site📍 La Jolla University of California, San Diego · Tests: A CDK4/6 inhibitor different from the first that the participant had received, plus fulvestrant., Treatment of physicia… A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer NCT06856200NA1 site📍 Shanghai Fudan University · Tests: Sirolimus (albumin - bound), Palbociclib, Fulvestrant Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors NCT06950086Phase 1, Phase 22 sites📍 Shanghai📍 Shanghai TYK Medicines, Inc · Tests: TYK-00540 First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors NCT05768139Phase 1, Phase 265 sites📍 Los Angeles📍 San Francisco📍 Aurora Eli Lilly and Company · Tests: STX-478, Fulvestrant, Ribociclib, Palbociclib, Letrozole A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy NCT05646862Phase 3210 sites📍 Greenbrae📍 Los Alamitos📍 Los Angeles Hoffmann-La Roche · Tests: Inavolisib, Fulvestrant, Alpelisib, Bupropion, Omeprazole Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors NCT06993844Phase 1, Phase 215 sites📍 Newport Beach📍 San Francisco📍 New Haven Ensem Therapeutics · Tests: ETX-636 dose escalation, ETX-636 dose escalation in combination with fulvestrant, ETX-636 dose expansion in combination… Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer NCT06380751Phase 3306 sites📍 Gilbert📍 Fountain Valley📍 Glendale AstraZeneca · Tests: Saruparib (AZD5305), Camizestrant, Abemaciclib, Ribociclib, Palbociclib Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC. NCT06705127Phase 21 site📍 Hangzhou First Affiliated Hospital of Zhejiang University · Tests: TORIPALIMAB INJECTION(JS001 ), Stereotactic Body Radiation Therapy (SBRT) A Study to Evaluate ATX-898 in Participants With Advanced Solid Tumors NCT07767474Phase 1, Phase 26 sites📍 Fort Worth📍 Houston📍 San Antonio Antares Therapeutics, Inc · Tests: ATX-898, ATX-898, ATX-898, ATX-898, ATX-898 Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced Breast Cancer NCT07285382Phase 22 sites📍 Dalian📍 Qingdao wanghaibo · Tests: Dalpiciclib 125mg, Dalpiciclib 150mg, Letrozole 2.5mg Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors NCT06726148Phase 1, Phase 233 sites📍 Los Angeles📍 Fort Myers📍 Boston Novartis Pharmaceuticals · Tests: ECI830, ribociclib, fulvestrant A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors NCT07318805Phase 113 sites📍 Duarte📍 Grand Rapids📍 Long Island City Pfizer · Tests: PF-08032562, Fulvestrant, Cetuximab, Fluorouracil, Oxaliplatin Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer NCT07604571Phase 111 sites📍 New Haven📍 Kansas City📍 Dallas Novartis Pharmaceuticals · Tests: IEV407, Fulvestrant, Letrozole To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer NCT07368998Phase 234 sites📍 Los Angeles📍 Jacksonville📍 Kansas City Hoffmann-La Roche · Tests: Inavolisib, Fulvestrant Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM NCT06974604Phase 21 site📍 Providence Brown University · Tests: Dexamethasone oral Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors NCT05985655Phase 1, Phase 215 sites📍 Los Angeles📍 Grand Rapids📍 New York Exscientia AI Ltd., a wholly owned subsidiary of Recursion … · Tests: GTAEXS617, SoC ABCSG 61 / TEODOR : Neoadjuvant TrEatment Optimization Driven by Circulating Tumor DNA and endOcrine Responsiveness NCT07084558NA14 sites📍 Vienna📍 Baden📍 Dornbirn Austrian Breast & Colorectal Cancer Study Group · Tests: blood sample for Signatera (TM) test, biopsy for Ki-67 assessment, FFPE tumor sample for Signatera (TM) test (archived) A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy NCT07071337Phase 32 sites📍 Beijing📍 Guangzhou Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Tests: SKB264, Nab-paclitaxel, Paclitaxel, Capecitabine
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy